MedPath

Study of NMB (Company's Name) Drug Ejecting Balloon for Arteriovenous Fistulae

Not Applicable
Conditions
Obstructive Lesions of Arteriovenous Dialysis Fistulae
Registration Number
NCT01538108
Lead Sponsor
N.M.B. Medical Applications Ltd
Brief Summary

The purpose of this study is to demonstrate the safety and effectiveness of the use of NMB's percutaneous transluminal angioplasty (PTA) Balloon.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • patients 18 years and older
  • Patients with arteriovenous fistula with obstructive lesion
  • Patient who is willing and able to sign a written informed consent
Exclusion Criteria
  • age < 18
  • female with child bearing potential
  • Previous participation in another study with any investigational drug or device within the past 30 days
  • Life expectancy of less than 12 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Restenosis Rate6 months
Secondary Outcome Measures
NameTimeMethod
Restenosis rate1,3 and 12 months
Easy insertion and removalintraprocedural
Major adverse eventsintraprocedural, 1, 3, 6 and 12 months

Trial Locations

Locations (1)

The Chaim Sheba Medical Center

🇮🇱

Tel Hashomer, Israel

The Chaim Sheba Medical Center
🇮🇱Tel Hashomer, Israel
Uri Rimon, MD
Contact
972-3-5302530

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.